Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback